Keep Me Logged In
Cole Smead, portfolio manager at Smead Capital Management, says that AbbVie's acquisition of Shire would be "very accretive" to shareholders and that the tax inversion part is not that important.
Got a confidential news tip? We want to hear from you.
Sign up for free newsletters and get more CNBC delivered to your inbox
© 2019 CNBC LLC. All Rights Reserved. A Division of NBCUniversal
Data is a real-time snapshot *Data is delayed at least 15 minutes. Global Business and Financial News, Stock Quotes, and Market Data and Analysis.
Data also provided by